Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Targeted therapies elicit seemingly paradoxical and poorly understood effects on tumor immunity. Here, we show that the MEK inhibitor trametinib abrogates cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) from human or mouse myeloid progenitors. MEK inhibition also reduced the production of the mMDSC chemotactic factor osteopontin by tumor cells. Together, these effects reduced mMDSC accumulation in tumor-bearing hosts, limiting the outgrowth of KRas–driven breast tumors, even though trametinib largely failed to directly inhibit tumor cell proliferation. Accordingly, trametinib impeded tumor progression in vivo through a mechanism requiring CD8+ T cells, which was paradoxical given the drug's reported ability to inhibit effector lymphocytes. Confirming our observations, adoptive transfer of tumor-derived mMDSC reversed the ability of trametinib to control tumor growth. Overall, our work showed how the effects of trametinib on immune cells could partly explain its effectiveness, distinct from its activity on tumor cells themselves. More broadly, by providing a more incisive view into how MEK inhibitors may act against tumors, our findings expand their potential uses to generally block mMDSC expansion, which occurs widely in cancers to drive their growth and progression. Cancer Res; 76(21); 6253–65. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationSmith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144 · cited 1×
“For instance, T cells, critical for controlling the growth of immunogenic tumors (1–4), require the Ras-MAPK signaling cascade following antigen activation for proliferation and effector function (5).”
BackgroundMittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742 · cited 1×
“Indeed, proper T-cell activation and proliferation is impaired by pharmacological inhibition of MEK signaling, both with the FDA-approved drug trametinib (6, 7) and other compounds (8).”
BackgroundLong, G. V., Fung, C., Menzies, A. M., Pupo, G. M., Carlino, M. S., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J. F., Saw, R. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6694 · Cited by 375 · cited 1×
“To extend our observations to the clinical use of trametinib, we analyzed published gene expression data of BRAFV600-mutant melanoma lesions biopsied from patients before and after treatment with trametinib plus dabrafenib (30).”
MethodKumar, V., Cheng, P., Condamine, T., Mony, S., Languino, L. R., McCaffrey, J. C., Hockstein, N., Guarino, M., Masters, G., Penman, E., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.014 · Cited by 371
Rutkowski, M. R., Stephen, T. L., Svoronos, N., Allegrezza, M. J., Tesone, A. J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J. M., Cadungog, M. G., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.009 · Cited by 311 · cited 1×
“To dissect the effects of trametinib treatment on other compartments of the immune-environment of solid tumors, we analyzed the effect of trametinib against the progression of transplantable Brpkp110 breast tumors, derived from syngeneic autochthonous p53/KRas/PI3K-driven primary breast adenocarcinomas (12, 17, 26).”
BackgroundSelf-citationVella, L. J., Pasam, A., Dimopoulos, N., Andrews, M., Knights, A., Puaux, A.-L., Louahed, J., Chen, W., Woods, K., & Cebon, J. S. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0181 · Cited by 139
Cited by
Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis
Erkes, D. A., Cai, W., Sanchez, I. M., Purwin, T. J., Rogers, C., Field, C. O., Berger, A. C., Hartsough, E. J., Rodeck, U., Alnemri, E. S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0672 · Cited by 459
“S3D and S3E), consistent with previous publications suggesting that MEKi inhibits T-cell function (21, 23).”
ResultImmunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumor growth
McKee, A. M., Kirkup, B. M., Madgwick, M., Fowler, W. J., Price, C. A., Dreger, S. A., Ansorge, R., Makin, K. A., Caim, S., Le Gall, G., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103012 · Cited by 81
Self-citation
Metadata
- Authors
- Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Perales-Puchalt, A., Nguyen, J. M., Payne, K. K., Singhal, S., Eruslanov, E. B., Tchou, J., & Conejo-Garcia, J. R.
- Venue
- Cancer Research
- Published
- 2016-10-31
- Volume
- 76
- Issue
- 21
- Pages
- 6253-6265
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2541831810
- Cited by
- 63
- References
- 8
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-1308
- The paper
- Allegrezza, M. J., Rutkowski, M. R., Stephen, T. L., Svoronos, N., Perales-Puchalt, A., Nguyen, J. M., Payne, K. K., Singhal, S., Eruslanov, E. B., Tchou, J., & Conejo-Garcia, J. R. (2016). Trametinib Drives T-cell–Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-1308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.